Rare blood clots from J&J and AstraZeneca vaccines are linked to an autoimmune reaction in genetically predisposed individuals, influencing future vaccine development.
Identifying and eliminating the trigger through genetic engineering is the focus for researchers to address the clotting issue associated with adenovirus-based vaccines.
[
Collection
]
[
|
...
]